165 related articles for article (PubMed ID: 15710887)
1. Concurrent suppression of hyperlipidemia and intestinal polyp formation by NO-1886, increasing lipoprotein lipase activity in Min mice.
Niho N; Mutoh M; Takahashi M; Tsutsumi K; Sugimura T; Wakabayashi K
Proc Natl Acad Sci U S A; 2005 Feb; 102(8):2970-4. PubMed ID: 15710887
[TBL] [Abstract][Full Text] [Related]
2. Concomitant suppression of hyperlipidemia and intestinal polyp formation by increasing lipoprotein lipase activity in Apc-deficient mice.
Mutoh M; Niho N; Wakabayashi K
Biol Chem; 2006 Apr; 387(4):381-5. PubMed ID: 16606335
[TBL] [Abstract][Full Text] [Related]
3. Concomitant suppression of hyperlipidemia and intestinal polyp formation in Apc-deficient mice by peroxisome proliferator-activated receptor ligands.
Niho N; Takahashi M; Kitamura T; Shoji Y; Itoh M; Noda T; Sugimura T; Wakabayashi K
Cancer Res; 2003 Sep; 63(18):6090-5. PubMed ID: 14522940
[TBL] [Abstract][Full Text] [Related]
4. Plasminogen activator inhibitor-1 (Pai-1) blockers suppress intestinal polyp formation in Min mice.
Mutoh M; Niho N; Komiya M; Takahashi M; Ohtsubo R; Nakatogawa K; Ueda K; Sugimura T; Wakabayashi K
Carcinogenesis; 2008 Apr; 29(4):824-9. PubMed ID: 18258607
[TBL] [Abstract][Full Text] [Related]
5. Improvement of hyperlipidemia by indomethacin in Min mice.
Niho N; Mutoh M; Komiya M; Ohta T; Sugimura T; Wakabayashi K
Int J Cancer; 2007 Oct; 121(8):1665-9. PubMed ID: 17546600
[TBL] [Abstract][Full Text] [Related]
6. Dose-dependent suppression of hyperlipidemia and intestinal polyp formation in Min mice by pioglitazone, a PPAR gamma ligand.
Niho N; Takahashi M; Shoji Y; Takeuchi Y; Matsubara S; Sugimura T; Wakabayashi K
Cancer Sci; 2003 Nov; 94(11):960-4. PubMed ID: 14611672
[TBL] [Abstract][Full Text] [Related]
7. Lipoprotein lipase activator ameliorates the severity of dietary steatohepatitis.
Yu J; Chu ES; Hui AY; Cheung KF; Chan HL; Leung WK; Farrell GC; Sung JJ
Biochem Biophys Res Commun; 2007 Apr; 356(1):53-9. PubMed ID: 17350593
[TBL] [Abstract][Full Text] [Related]
8. Suppression of N-nitrosobis(2-oxopropyl)amine-induced pancreatic carcinogenesis in hamsters by pioglitazone, a ligand of peroxisome proliferator-activated receptor gamma.
Takeuchi Y; Takahashi M; Sakano K; Mutoh M; Niho N; Yamamoto M; Sato H; Sugimura T; Wakabayashi K
Carcinogenesis; 2007 Aug; 28(8):1692-6. PubMed ID: 17449904
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of intestinal polyp formation by pitavastatin, a HMG-CoA reductase inhibitor.
Teraoka N; Mutoh M; Takasu S; Ueno T; Yamamoto M; Sugimura T; Wakabayashi K
Cancer Prev Res (Phila); 2011 Mar; 4(3):445-53. PubMed ID: 21233289
[TBL] [Abstract][Full Text] [Related]
10. [Effect of propylene glycol mannate sulfate on blood lipids and lipoprotein lipase in hyperlipidemic rat].
Gao Y; Yu WG; Han F; Lu XZ; Gong QH; Hu XK; Guan HS
Yao Xue Xue Bao; 2002 Sep; 37(9):687-90. PubMed ID: 12567891
[TBL] [Abstract][Full Text] [Related]
11. Effect of niacin on adipocyte leptin in hypercholesterolemic rabbits.
Yang J; Zhao SP; Li J; Dong SZ
Cardiovasc Pathol; 2008; 17(4):219-25. PubMed ID: 18402819
[TBL] [Abstract][Full Text] [Related]
12. Enhanced aortic atherosclerosis in transgenic Watanabe heritable hyperlipidemic rabbits expressing lipoprotein lipase.
Koike T; Liang J; Wang X; Ichikawa T; Shiomi M; Sun H; Watanabe T; Liu G; Fan J
Cardiovasc Res; 2005 Feb; 65(2):524-34. PubMed ID: 15639492
[TBL] [Abstract][Full Text] [Related]
13. Ciprofibrate treatment decreases non-high density lipoprotein cholesterol and triglycerides and increases high density lipoprotein cholesterol in patients with Frederickson type IV dyslipidemia phenotype.
Bermúdez-Pirela V; Souki A; Cano-Ponce C; Bermúdez-Arias F; Mengual-Moreno E; Leal-Gonzalez E; Lemus-Antepaz M; de Bravo MC; de Díaz AA; de Pirela NL; Cano-Peñaloza R; Puche-Medina G; Arraiz N; Reyna-Villazmil N; Contreras F; Israili ZH; Valasco M
Am J Ther; 2007; 14(2):213-20. PubMed ID: 17414592
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of low-density lipoprotein receptor and lipid accumulation in intestinal polyps in Min mice.
Mutoh M; Komiya M; Teraoka N; Ueno T; Takahashi M; Kitahashi T; Sugimura T; Wakabayashi K
Int J Cancer; 2009 Dec; 125(11):2505-10. PubMed ID: 19544529
[TBL] [Abstract][Full Text] [Related]
15. Effects of NO-1886, a lipoprotein lipase promoting agent, on homozygous and heterozygous Watanabe heritable hyperlipidaemic rabbits.
Tsutsumi K; Inoue Y; Murase T
Arzneimittelforschung; 2000 Feb; 50(2):118-21. PubMed ID: 10719613
[TBL] [Abstract][Full Text] [Related]
16. Salacia oblonga root improves postprandial hyperlipidemia and hepatic steatosis in Zucker diabetic fatty rats: activation of PPAR-alpha.
Huang TH; Peng G; Li GQ; Yamahara J; Roufogalis BD; Li Y
Toxicol Appl Pharmacol; 2006 Feb; 210(3):225-35. PubMed ID: 15975614
[TBL] [Abstract][Full Text] [Related]
17. Relationship between plasma HDL subclasses distribution and lipoprotein lipase gene HindIII polymorphism in hyperlipidemia.
Long S; Tian Y; Zhang R; Yang L; Xu Y; Jia L; Fu M
Clin Chim Acta; 2006 Apr; 366(1-2):316-21. PubMed ID: 16364275
[TBL] [Abstract][Full Text] [Related]
18. Lipoprotein lipase activation by red ginseng saponins in hyperlipidemia model animals.
Inoue M; Wu CZ; Dou DQ; Chen YJ; Ogihara Y
Phytomedicine; 1999 Oct; 6(4):257-65. PubMed ID: 10589445
[TBL] [Abstract][Full Text] [Related]
19. Astragalus mongholicus and Angelica sinensis compound alleviates nephrotic hyperlipidemia in rats.
Li J; Yu L; Li N; Wang H
Chin Med J (Engl); 2000 Apr; 113(4):310-4. PubMed ID: 11775225
[TBL] [Abstract][Full Text] [Related]
20. Effects of polydatin from Polygonum cuspidatum on lipid profile in hyperlipidemic rabbits.
Xing WW; Wu JZ; Jia M; Du J; Zhang H; Qin LP
Biomed Pharmacother; 2009 Aug; 63(7):457-62. PubMed ID: 18657948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
